- ICH GCP
- Rejestr badań klinicznych w USA
- Badanie kliniczne NCT07645105
Body Weight Reduction and Metabolic/Biochemical Parameters in Overweight or Obesity
The Effect of Body Weight Reduction on Selected Metabolic and Biochemical Parameters in Individuals With Overweight or Obesity
Przegląd badań
Status
Interwencja / Leczenie
Szczegółowy opis
This was a single-center prospective observational cohort study conducted at the Medical University of Silesia in Katowice, Poland, and in a metabolic outpatient clinic in Miasteczko Śląskie, Poland. The study was designed to evaluate the effect of body weight reduction on selected metabolic, biochemical, oxidative-stress, inflammatory, and body-composition parameters in individuals with overweight or obesity.
The study was conducted in the context of routine metabolic outpatient care. Participants with overweight or obesity received standard lifestyle-based body weight reduction management, including individualized dietary recommendations, physical-activity guidance, health education, and regular follow-up visits. The investigators did not assign participants to an investigational medicinal product, medical device, dietary supplement, surgical procedure, pharmacological intervention, or experimental therapy. The study prospectively observed participants receiving routine lifestyle-based weight reduction management and assessed changes in clinical and laboratory parameters before and after body weight reduction.
The approved study protocol planned the inclusion of individuals with overweight or obesity and a normal-weight comparison group. Participants with BMI > 25 kg/m² were evaluated in relation to body weight reduction, while individuals with normal body weight served as a comparison group for selected baseline analyses. Patients with overweight or obesity were assessed by medical examination, dietary and clinical questionnaires, anthropometric measurements, body-composition analysis, and fasting blood sampling. Body-composition analysis included assessment of body weight, fat mass, fat-free mass, skeletal muscle mass, total body water, visceral fat, and related parameters. Blood samples were collected for biochemical analyses, including markers of glucose metabolism, lipid metabolism, oxidative stress, antioxidant status, inflammatory markers, adipokines, cytokines, chemokines, growth factors, and selected cardiovascular-risk parameters.
Participants with overweight or obesity were followed during standard body weight reduction management until clinically relevant weight reduction or achievement of optimal body weight. According to the original study documentation, assessments were planned before the start of weight reduction, after approximately 10% body weight reduction, and after approximately 20% body weight reduction or achievement of target body weight. Follow-up visits included body weight measurements, waist and hip circumference measurements, dietary counselling, education regarding caloric intake, and motivation to continue lifestyle modification.
The primary objective of the study was to assess whether body weight reduction in individuals with overweight or obesity is associated with changes in selected metabolic and biochemical parameters. Secondary objectives included evaluation of oxidative-stress and antioxidant-status parameters, glucose and lipid metabolism, inflammatory markers, adipokines, cytokines, and body-composition changes. The study also aimed to assess relationships between biochemical parameters and body-composition indices before and after body weight reduction.
The study was approved by the Bioethics Committee of the Medical University of Silesia in Katowice, Poland. All participants received information about the study and provided written informed consent before participation. This ClinicalTrials.gov record is submitted retrospectively to meet journal publication requirements and to provide transparent public information about the completed study.
Typ studiów
Zapisy (Rzeczywisty)
Kontakty i lokalizacje
Lokalizacje studiów
-
-
Silesian Voivodeship
-
Miasteczko Śląskie, Silesian Voivodeship, Polska, 42-610
- Eko-Prof-Med Medical Center, Metabolic Outpatient Clinic
-
Zabrze, Silesian Voivodeship, Polska, 41-808
- Department of Biochemistry, Faculty of Medical Sciences in Zabrze, Medical University of Silesia in Katowice
-
-
Kryteria uczestnictwa
Kryteria kwalifikacji
Wiek uprawniający do nauki
- Dorosły
- Starszy dorosły
Akceptuje zdrowych ochotników
Metoda próbkowania
Badana populacja
Opis
Inclusion Criteria:
- Adults aged 18-85 years
- BMI > 25 kg/m²
- Overweight or obesity diagnosed on the basis of medical examination and body-composition assessment
- Participation in routine lifestyle-based body weight reduction management in a metabolic outpatient clinic
- Written informed consent to participate in the study
Exclusion Criteria:
- Lack of informed consent
- Severe hepatic insufficiency
- Severe renal insufficiency
- Severe respiratory insufficiency
- Severe circulatory insufficiency
- Disturbances of consciousness
- Treatment-resistant depression
- Chronic alcohol abuse
- Pregnancy
- History of serious nervous system injury
- Implanted cardiac pacemaker
- Pharmacological treatment affecting glucose and/or lipid metabolism
- Incomplete follow-up or incomplete laboratory data
Plan studiów
Jak projektuje się badanie?
Szczegóły projektu
Kohorty i interwencje
Grupa / Kohorta |
Interwencja / Leczenie |
|---|---|
|
Individuals With Overweight or Obesity
Adults with BMI > 25 kg/m² who were receiving routine lifestyle-based body weight reduction management in a metabolic outpatient clinic.
Participants were prospectively observed and assessed before and after body weight reduction.
Assessments included clinical and dietary questionnaires, anthropometric measurements, body-composition analysis, fasting blood sampling, and biochemical, metabolic, oxidative-stress, inflammatory, adipokine, and cytokine measurements.
|
Standard lifestyle-based body weight reduction management received as part of routine metabolic outpatient care.
It included individualized dietary recommendations, physical-activity guidance, health education, and regular follow-up visits.
Participants were not assigned to this management as part of the study; the study prospectively observed patients receiving routine care and assessed metabolic, biochemical, inflammatory, oxidative-stress, adipokine, cytokine, and body-composition parameters before and after body weight reduction.
|
Co mierzy badanie?
Podstawowe miary wyniku
Miara wyniku |
Opis środka |
Ramy czasowe |
|---|---|---|
|
Change in Body Weight
Ramy czasowe: Baseline and after body weight reduction, up to approximately 6 months
|
Change in body weight from baseline to follow-up after routine lifestyle-based body weight reduction management.
|
Baseline and after body weight reduction, up to approximately 6 months
|
Miary wyników drugorzędnych
Miara wyniku |
Opis środka |
Ramy czasowe |
|---|---|---|
|
Change in Body Fat Mass
Ramy czasowe: Baseline and after body weight reduction, up to approximately 6 months
|
Change in body fat mass assessed by bioelectrical impedance analysis and expressed in kilograms.
|
Baseline and after body weight reduction, up to approximately 6 months
|
|
Change in Glucose concentration in mg/dl.
Ramy czasowe: Baseline and after body weight reduction, up to approximately 6 months
|
Changes in fasting glucose.
|
Baseline and after body weight reduction, up to approximately 6 months
|
|
Change in total-cholesterol concentration in mg/dl.
Ramy czasowe: Baseline and after body weight reduction, up to approximately 6 months
|
Changes in total cholesterol concentration.
|
Baseline and after body weight reduction, up to approximately 6 months
|
|
Change in malondialdehyde concentration in μmol/l.
Ramy czasowe: Baseline and after body weight reduction, up to approximately 6 months
|
Change in blood malondialdehyde concentration, assessed as a marker of lipid peroxidation and oxidative stress, from baseline to follow-up after body weight reduction.
|
Baseline and after body weight reduction, up to approximately 6 months
|
|
Change in serum IL-6 concentration in pg/ml.
Ramy czasowe: Baseline and after body weight reduction, up to approximately 6 months
|
Change in serum interleukin-6 (IL-6) concentration from baseline to follow-up after body weight reduction.
IL-6 was measured in serum samples as a marker of systemic low-grade inflammation and expressed in pg/ml.
|
Baseline and after body weight reduction, up to approximately 6 months
|
Współpracownicy i badacze
Sponsor
Śledczy
- Główny śledczy: Sławomir Kasperczyk, Prof, Medical University of Silesia in Katowice
Publikacje i pomocne linki
Publikacje ogólne
- Szlachta B, Birkova A, Cizmarova B, Glogowska-Gruszka A, Zalejska-Fiolka P, Dydon M, Zalejska-Fiolka J. Erythrocyte Oxidative Status in People with Obesity: Relation to Tissue Losses, Glucose Levels, and Weight Reduction. Antioxidants (Basel). 2024 Aug 7;13(8):960. doi: 10.3390/antiox13080960.
- Szlachta B, Birkova A, Wielkoszynski T, Gospodarczyk A, Hubkova B, Dydon M, Zalejska-Fiolka J. Serum Oxidative Status in People with Obesity: Relation to Tissue Losses, Glucose Levels, and Weight Reduction. Antioxidants (Basel). 2023 Oct 27;12(11):1923. doi: 10.3390/antiox12111923.
- Zalejska-Fiolka J, Birkova A, Hubkova B, Wielkoszynski T, Cizmarova B, Szlachta B, Fiolka R, Blaszczyk U, Wylegala A, Kasperczyk S, Grzanka A, Marekova M, Toborek M. Successful correction of hyperglycemia is critical for weight loss and a decrease in cardiovascular risk in obese patients. J Nutr Biochem. 2022 Aug;106:109021. doi: 10.1016/j.jnutbio.2022.109021. Epub 2022 Apr 25.
- Zalejska-Fiolka J, Birkova A, Wielkoszynski T, Hubkova B, Szlachta B, Fiolka R, Blaszczyk U, Kuzan A, Gamian A, Marekova M, Toborek M. Loss of Skeletal Muscle Mass and Intracellular Water as Undesired Outcomes of Weight Reduction in Obese Hyperglycemic Women: A Short-Term Longitudinal Study. Int J Environ Res Public Health. 2022 Jan 17;19(2):1001. doi: 10.3390/ijerph19021001.
- Zalejska-Fiolka J, Hubkova B, Birkova A, Velika B, Puchalska B, Kasperczyk S, Blaszczyk U, Fiolka R, Bozek A, Maksym B, Marekova M, Birkner E. Prognostic Value of the Modified Atherogenic Index of Plasma during Body Mass Reduction in Polish Obese/Overweight People. Int J Environ Res Public Health. 2018 Dec 27;16(1):68. doi: 10.3390/ijerph16010068.
Daty zapisu na studia
Główne daty studiów
Rozpoczęcie studiów (Rzeczywisty)
Zakończenie podstawowe (Rzeczywisty)
Ukończenie studiów (Rzeczywisty)
Daty rejestracji na studia
Pierwszy przesłany
Pierwszy przesłany, który spełnia kryteria kontroli jakości
Pierwszy wysłany (Rzeczywisty)
Aktualizacje rekordów badań
Ostatnia wysłana aktualizacja (Rzeczywisty)
Ostatnia przesłana aktualizacja, która spełniała kryteria kontroli jakości
Ostatnia weryfikacja
Więcej informacji
Terminy związane z tym badaniem
Słowa kluczowe
Dodatkowe istotne warunki MeSH
- Zaburzenia odżywiania
- Choroby metaboliczne
- Przekarmienie
- Masy ciała
- Zaburzenia metabolizmu glukozy
- Insulinooporność
- Hiperinsulinizm
- Stany patologiczne, oznaki i objawy
- Choroby żywieniowe i metaboliczne
- Objawy i symptomy
- Nadwaga
- Otyłość
- Syndrom metabliczny
- Otyłość, brzuch
- Abdominal obesity metabolic syndrome
Inne numery identyfikacyjne badania
- KNW/0022/KB1/19/I/16
- Secondary ID: KNW-1-016/N/7/2 (Inny numer grantu/finansowania: Medical University of Silesia)
- Secondary ID: KNW-1/109/K/8/Z (Inny identyfikator: Medical University of Silesia)
- Secondary ID: KNW-1/171/K/9/O (Inny identyfikator: Medical University of Silesia)
- Secondary ID: PCN-1-049/K/0/O (Inny identyfikator: Medical University of Silesia)
- Secondary ID: PCN-1-018/K/1/O (Inny identyfikator: Medical University of Silesia)
- Secondary ID: PCN-1-132/K/2/O (Inny identyfikator: Medical University of Silesia)
Plan dla danych uczestnika indywidualnego (IPD)
Planujesz udostępniać dane poszczególnych uczestników (IPD)?
Opis planu IPD
Informacje o lekach i urządzeniach, dokumenty badawcze
Bada produkt leczniczy regulowany przez amerykańską FDA
Bada produkt urządzenia regulowany przez amerykańską FDA
Te informacje zostały pobrane bezpośrednio ze strony internetowej clinicaltrials.gov bez żadnych zmian. Jeśli chcesz zmienić, usunąć lub zaktualizować dane swojego badania, skontaktuj się z register@clinicaltrials.gov. Gdy tylko zmiana zostanie wprowadzona na stronie clinicaltrials.gov, zostanie ona automatycznie zaktualizowana również na naszej stronie internetowej .